Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan ...

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P.

Friday, Aurora Therapeutics debuted with $16 million in seed capital from Menlo Ventures. Its goal: To develop the industry’s ...

Hair loss–focused Veradermics and cancer biotech Eikon follow the lead of Aktis Oncology, which last week announced a $318 ...

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are ...

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

In his annual letter, Flagship Pioneering’s Noubar Afeyan lays out a choice between near-term “human-made miracles” and a ...

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after ...

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told ...

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...